NOVEN
TO PRESENT AT FTN MIDWEST SECURITIES |
BackMiami, FL, May
31, 2007 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
that Robert C. Strauss, its President, CEO & Chairman, is scheduled
to provide an update on Noven’s business and prospects at the
FTN Midwest Securities Health Care Conference in New York City on Tuesday,
June 5, 2007, at 1:20 p.m. Eastern Time. The public is invited to listen
to the presentation live via webcast at www.noven.com, and a replay
will be available for at least two weeks at the same site.
Noven Pharmaceuticals,
Inc., headquartered in Miami, Florida, is a leading developer of advanced
transdermal drug delivery technologies and prescription transdermal
products. Noven’s prescription patches are approved in over 30
countries and include Vivelle-Dot® (the most prescribed estrogen
patch in the U.S.) and Daytrana™ (the first and only patch approved
for the treatment of ADHD). Noven is committed to expanding the universe
of available transdermal therapies for the benefit of patients, partners
and shareholders. See www.noven.com for additional information.
| Contact: Alina Bowman Investor Relations Coordinator (305) 253-1916 |
Copyright © 2007 Noven Pharmaceuticals, Inc. All rights reserved.